Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
Adam J. Fein, Ph.D.
HMP Global, a healthcare education company, will acquire Drug Channels Institute. Founded in 2006 by Adam J. Fein, Ph.D., Drug Channels is a market intelligence company focused on the pharmaceutical industry. It provides webinars and industry reports on pharmaceutical economic issues and drug supply and distribution. Terms of the agreement were not disclosed.
As part of the integration, Drug Channels leadership will remain in place, with Fein becoming president, Drug Channels Institute, and Paula Fein assuming the role of vice president, business development.
Adam Fein is a well-known thought leader in the pharmaceutical industry providing insight and analysis on drug pricing, pharmacy benefit managers, the specialty drug market, drug reimbursement, and healthcare reform. He is known for his humor in making the industry more accessible for readers.
On a blog post on the Drug Channels website, Adam Fein said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
HMP produces in person and virtual medical education events and provides news and clinical information for healthcare providers. It produces about 50 journals/websites and 400 events and serves oncology, neurology, psychiatry and behavioral health, gastroenterology, cardiovascular, dermatology and rheumatology.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More